栗占国，主任医师，教授，博士生导师，北京大学人民医院临床免疫中心主任，医学部风湿免疫学系主任，北京大学临床免疫中心主任。

973首席科学家, 国家杰出青年基金获得者, 获吴杨医学奖和北京大学国华杰出学者奖。

中国医促会风湿免疫分会主委，中国免疫学会自身免疫分会主委，中华医学会风湿免疫分会前主委，国际风湿病联盟(ILAR)和亚太风湿病联盟(APLAR)前主席。

《 Rheumatology Autoimmunity 》主编，《中华风湿病学杂志》名誉主编。在Nat Med, Science及Lancet Rheum等发表SCI论文500余篇，入选爱思唯尔中国高被引学者。

代表性文章：

1. He, J, Sun X, Li, Z. Low dose IL-2 for patients with systemic lupus erythematosus. The Lancet Rheumatology. 2019 Dec;1(4): e203.（IF 8.136）
2. Li, Z., He, J. Yu, D. The rise of IL-2 therapy — a picture beyond Treg cells. Nat Rev Rheumato. 2017 May. 386. （IF 20.543）
3. Sun X, Li R, Cai Y, Al-Herz A, Lahiri M, Choudhury MR, Hidayat R, Suryana BPP, Kaneko Y, Fujio K, Van Hung N, Pandya S, Pang LK, Katchamart W, Sigdel KR, Paudyal B, Narongroeknawin P, Chevaisrakul P, Sun F, Lu Y, Ho C, Yeap SS, Li Z; APLAR RA SIG group. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac. 2021 Aug;15:100240.
4. He J, Chu Y, Li J, Meng Q, Liu Y, Jin J, Wang Y, Wang J, Huang B, Shi L, Shi X, Tian J, Zhufeng Y, Feng R, Xiao W, Gan Y, Guo J, Shao C, Su Y, Hu F, Sun X, Yu J, Kang Y, Li Z. Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis. Sci Adv. 2022 Feb;8(6):eabm1511.（IF 14.136）
5. Mu R, Li C, Li X, Ke Y, Zhao L, Chen L, Wu R, Wu Z, Zuo X, Xie Y, Chen J, Wei W, Liu Y, Li Z, Dai L, Sun L, Liu X, Li Z. Effectiveness and safety of Iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. Lancet Reg Health West Pac. 2021 Mar; 10:100128.
6. Chen X, Sun X, Yang W, Yang B, Zhao X, Chen S, He L, Chen H, Yang C, Xiao L, Chang Z, Guo J, He J, Zhang F, Zheng F, Hu Z, Yang Z, Lou J, Zheng W, Qi H, Xu C, Zhang H, Shan H, Zhou XJ, Wang Q, Shi Y, Lai L, Li Z, Liu W. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. Science. 2018 Nov;362(6415):700-705. （IF 47.728）
7. Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, Zhang X, Li Y, Zhou Y, Yang Y, Li R, Yao H, Liu Y, Li C, Li Y, Ren L, Su Y, Sun X, He J, Li Z. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. STTT. 2022 Mar;7(1):67.（IF 18.187）
8. Hu F, Jiang X, Guo C, Li Y, Chen S, Zhang W, Du Y, Wang P, Zheng X, Fang X, Li X, Song J, Xie Y, Huang F, Xue J, Bai M, Jia Y, Liu X, Ren L, Zhang X, Guo J, Pan H, Su Y, Yi H, Ye H, Zuo D, Li J, Wu H, Wang Y, Li R, Liu L, Wang XY, Li ZG. Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study. Nat Commun. 2020 Apr; 11(1):1911. (IF 11.878)
9. He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z. Low-dose interleukin-2 treatment modulates CD4+ T cell subsets selectively in patients with systemic lupus erythematosus. Nat Med. 2016 Sep; 22(9):991-3. (IF 30.357)
10. Liu Y, Mu R, Gao YP, Dong J, Zhu L, Ma Y, Li YH, Zhang HQ, Han D, Zhang Y, McInnes IB, Zhang J, Shen B, Yang G, Li ZG. A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host Microbe. 2016 Mar;19(3):400-8.（IF 609）
11. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Karnowski A, Belz GT, Ghali JR, Cook MC, Riminton DS, Veillette A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li ZG, Yu D. Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺CD4⁺T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013; 39(4):770-81. (IF19.748)
12. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug;159(4):253-61. (IF= 17.81）
13. Hu F, Mu R, Zhu J, Shi L, Li Y, Liu X, Shao W, Li G, Li M, Su Y, Cohen PL, Qiu X, Li ZG. Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis. 2014 May; 73(5):928-36. （IF 12.38）
14. Wang T, Sun X, Zhao J, Zhang J, Zhu H, Li C, Gao N, Jia Y, Xu D, Huang FP, Li N, Lu L, Li ZG. Regulatory t cells in rheumatoid arthritis showed increased plasticity toward th17 but retained suppressive function in peripheral blood. Ann Rheum Dis. 2015; 74 (6):1293-1301.（IF 14.299）
15. Du Y, Su Y, He J, Yang Y, Shi Y, Cui Y, Luo C, Wu X, Liu X, Hu F, Ma X, Zheng L, Zhang J, Zuo X, Sheng Y, Wu L,Zhang X, Guo J, Li ZG. Ann Rheum Dis. Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome. Ann Rheum Dis. 2015; 74(11): 2070-5. （IF 14.299）